Total Payments
$123,976
2024 Payments
$93.97
Companies
13
Transactions
274
Medicare Patients
5,865
Medicare Billing
$831,401
Payment Breakdown by Category
Other$112,119 (90.4%)
Food & Beverage$6,242 (5.0%)
Travel$4,139 (3.3%)
Consulting$1,438 (1.2%)
Education$38.10 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $111,957 | 49 | 90.3% |
| Food and Beverage | $6,242 | 203 | 5.0% |
| Travel and Lodging | $4,139 | 15 | 3.3% |
| Consulting Fee | $1,438 | 2 | 1.2% |
| Debt forgiveness | $162.00 | 1 | 0.1% |
| Education | $38.10 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $101,129 | 114 | $0 (2023) |
| Amgen Inc. | $19,102 | 31 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,238 | 81 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,190 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $554.64 | 30 | $0 (2023) |
| Abbott Laboratories | $265.42 | 3 | $0 (2019) |
| Medtronic Vascular, Inc. | $207.84 | 5 | $0 (2020) |
| Welch Allyn | $162.00 | 1 | $0 (2021) |
| Actelion Pharmaceuticals US, Inc. | $50.03 | 1 | $0 (2017) |
| Medtronic, Inc. | $27.51 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $93.97 | 4 | E.R. Squibb & Sons, L.L.C. ($65.94) |
| 2023 | $1,213 | 10 | Amgen Inc. ($732.63) |
| 2022 | $18,316 | 41 | Janssen Pharmaceuticals, Inc ($14,958) |
| 2021 | $22,271 | 46 | Amgen Inc. ($13,681) |
| 2020 | $13,622 | 31 | Janssen Pharmaceuticals, Inc ($11,977) |
| 2019 | $29,073 | 50 | Janssen Pharmaceuticals, Inc ($28,622) |
| 2018 | $25,539 | 50 | Janssen Pharmaceuticals, Inc ($25,018) |
| 2017 | $13,850 | 42 | Janssen Pharmaceuticals, Inc ($13,255) |
All Payment Transactions
274 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.98 | General |
| Category: Cardiovascular | ||||||
| 07/01/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $25.56 | General |
| Category: Cardiovascular | ||||||
| 03/25/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: Cardiology | ||||||
| 02/26/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.40 | General |
| Category: Cardiovascular | ||||||
| 11/20/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $30.16 | General |
| Category: Cardiovascular | ||||||
| 10/04/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/28/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.66 | General |
| Category: Cardiovascular | ||||||
| 05/22/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $24.95 | General |
| Category: Cardiovascular | ||||||
| 05/16/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/15/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: Cardiology | ||||||
| 04/11/2023 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/23/2023 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.50 | General |
| Category: Cardiology | ||||||
| 03/07/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/13/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.93 | General |
| Category: Cardiovascular | ||||||
| 12/15/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.68 | General |
| Category: Cardiovascular | ||||||
| 12/13/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Cardiology | ||||||
| 11/18/2022 | Amgen Inc. | — | Education | In-kind items and services | $17.26 | General |
| 11/04/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $6.08 | General |
| Category: Cardiovascular | ||||||
| 10/14/2022 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/03/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $27.63 | General |
| Category: Cardiovascular | ||||||
| 10/03/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $0.46 | General |
| Category: Cardiovascular | ||||||
| 09/20/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $89.00 | General |
| Category: Cardiovascular | ||||||
| 09/19/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $11.22 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/15/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $3.11 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,208 | 2,506 | $531,316 | $135,118 |
| 2022 | 17 | 1,283 | 2,612 | $543,983 | $197,214 |
| 2021 | 21 | 1,590 | 3,130 | $688,664 | $257,553 |
| 2020 | 23 | 1,784 | 3,310 | $602,037 | $241,516 |
Total Patients
5,865
Total Services
11,558
Medicare Billing
$831,401
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 267 | 394 | $65,670 | $33,039 | 50.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 187 | 198 | $74,250 | $27,995 | 37.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 56 | 487 | $243,500 | $24,813 | 10.2% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 46 | 367 | $18,350 | $6,693 | 36.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 23 | 28 | $8,400 | $5,970 | 71.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 38 | $8,056 | $4,805 | 59.7% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 24 | 25 | $9,900 | $4,227 | 42.7% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 50 | 76 | $8,132 | $3,973 | 48.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 265 | 382 | $18,336 | $3,833 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 54 | $6,642 | $3,352 | 50.5% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 18 | 18 | $14,832 | $3,240 | 21.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 20 | $5,500 | $2,467 | 44.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 55 | 117 | $6,435 | $2,295 | 35.7% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 13 | 119 | $11,900 | $2,151 | 18.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $4,318 | $2,009 | 46.5% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 62 | 133 | $15,295 | $1,910 | 12.5% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 13 | 19 | $7,600 | $1,579 | 20.8% |
| 33285 | Insertion of heart rhythm monitor under skin | Facility | 2023 | 14 | 14 | $4,200 | $766.33 | 18.2% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2022 | 64 | 527 | $263,500 | $84,246 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 283 | 387 | $59,985 | $34,014 | 56.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 205 | 216 | $81,000 | $31,861 | 39.3% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2022 | 56 | 411 | $20,550 | $8,073 | 39.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 41 | $8,692 | $5,279 | 60.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 293 | 396 | $19,008 | $3,941 | 20.7% |
| 93280 | Programming of dual lead pacemaker system | Office | 2022 | 50 | 67 | $7,169 | $3,764 | 52.5% |
About Dr. Gregory Singer, M.D
Dr. Gregory Singer, M.D is a Cardiovascular Disease healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114010865.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Singer, M.D has received a total of $123,976 in payments from pharmaceutical and medical device companies, with $93.97 received in 2024. These payments were reported across 274 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($111,957).
As a Medicare-enrolled provider, Singer has provided services to 5,865 Medicare beneficiaries, totaling 11,558 services with total Medicare billing of $831,401. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location Rochester, NY
- Active Since 10/02/2006
- Last Updated 02/05/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1114010865
Products in Payments
- XARELTO (Drug) $101,129
- Repatha (Biological) $19,055
- MULTAQ (Drug) $1,190
- ELIQUIS (Drug) $1,141
- ENTRESTO (Drug) $460.31
- Confirm Rx (Device) $166.13
- None (Device) $162.00
- CAMZYOS (Drug) $109.98
- CRT-Ds (Device) $99.29
- LEQVIO (Drug) $94.33
- Advisa (Device) $93.41
- Visia AF (Device) $82.70
- Reveal LINQ (Device) $30.31
- Corlanor (Drug) $29.16
- Azure (Device) $28.93
- MetaCross (Device) $21.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Rochester
Samuel Asirvatham, M.d, M.D
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Srijoy Mahapatra, M.d, M.D
Cardiovascular Disease — Payments: $1.2M
Cardiovascular Disease $1.2M
Amir Lerman, M.d, M.D
Cardiovascular Disease — Payments: $590,259
Cardiovascular Disease $590,259
Charanjit Rihal, M.d, M.D
Cardiovascular Disease — Payments: $484,688
Cardiovascular Disease $484,688
Martha Grogan, M.d, M.D
Cardiovascular Disease — Payments: $402,326
Cardiovascular Disease $402,326
David Hayes, M.d, M.D
Cardiovascular Disease — Payments: $278,959
Cardiovascular Disease $278,959